Newronika
Newronika is an Italian neurotechnology company developing the αDBS adaptive deep brain stimulation platform, which continuously monitors brain signals and automatically adjusts stimulation for Parkinson's disease patients. The CE-marked system is sold to hospitals and movement disorder clinics across the European Economic Area.
- Company typePrivate
- Founded2011
- HeadquartersMilan, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Newronika does
Newronika S.p.A. is an Italian neurotechnology company founded in 2011 as a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, built on over 20 years of academic research into adaptive deep brain stimulation. The company develops the αDBS (AlphaDBS) platform, a CE-marked adaptive closed-loop deep brain stimulation system for Parkinson's disease that continuously senses patient brain signals minute-by-minute and automatically adjusts stimulation parameters in real time. Core technical components include a patented proportional control algorithm that linearly tracks neural biomarkers, full-spectrum α/β brain signal sensing captured every 10 minutes with asymmetric sensing during stimulation, the WebBioBank cloud-based neural data platform that aggregates longitudinal implant data for AI-powered therapy optimization and biomarker discovery, and a remote patient monitoring module that enables at-home data collection and reduces in-clinic visit burden.
The company sells implantable adaptive DBS hardware systems directly to hospitals, academic medical centers, and specialized movement disorder clinics in the European Economic Area, supported by field-based Clinical Field Engineers and Clinical Scientists who provide procedural support, programming training, and ongoing clinical partnership. A US subsidiary (Newronika USA Inc., Goose Creek, South Carolina) supports an FDA Investigational Device Exemption-approved clinical trial as a precursor to U.S. commercial launch. Clinical validation comes from a double-blind randomized crossover study (N=19, Parkinson's Disease) showing 86% patient preference for αDBS over conventional DBS, +23% additional waking hours with good symptom relief, and 2.4× longer continuous symptom relief versus a leading competitor; 100% of replacement patients with prior conventional DBS preferred aDBS.
Newronika has raised approximately €30.2 million in cumulative funding across a 2016 venture round (€1.7M), a 2019 Series A (€8.4M), EIC Accelerator grant and blended finance (€4.5M total, 2022-2024), and a 2025 Series B (€13.6M / $14.1M) from investors including Innogest Capital, Indaco Venture Partners, F3F, Omnes Capital, ENEA Tech e Biomedical, TNBT Capital, Wille Finance, Atlante Ventures, and the Michael J. Fox Foundation. The company's leadership combines co-founder technical leadership (Lorenzo Rossi, CEO & CTO; Alberto Priori, SAB Chairman) with recently appointed strategic oversight (Keith Carlton, Executive Chairman, September 2025).
Newronika firmographics
Firmographics- Name
- Newronika
- Legal name
- Newronika S.p.A.
- Website
- https://newronika.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Newronika is an Italian neurotechnology company developing the αDBS adaptive deep brain stimulation platform, which continuously monitors brain signals and automatically adjusts stimulation for Parkinson's disease patients. The CE-marked system is sold to hospitals and movement disorder clinics across the European Economic Area.
- Ownership category
- akta.pro rank
Newronika industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where Newronika is headquartered
LocationHeadquarters
- HQ city
- Milan
- HQ country
- Italy
- HQ region
- Europe
Offices3 records
Markets served
Newronika business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Adaptive DBS Hardware and Implant Systems: Sale of implantable adaptive deep brain stimulation devices and associated hardware components. The αDBS system is CE marked and commercially available in the European Economic Area, generating revenue through device sales to hospitals and clinics.
- Clinical Support and Professional Services: Field-based clinical engineering and scientific support services provided to healthcare institutions implementing the aDBS platform, including training, programming support, and ongoing therapy optimization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Adaptive DBS System (αDBS) |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Newronika product offering
Product offeringCore offering
Newronika develops and sells the αDBS (AlphaDBS) adaptive deep brain stimulation platform, an implantable neurostimulation system for Parkinson's disease patients. The platform combines closed-loop implantable hardware, a patented proportional control algorithm, full-spectrum brain sensing, and the WebBioBank cloud-based AI data platform, with remote patient monitoring capabilities. The system is CE-marked and commercially available in the European Economic Area, sold to hospitals and specialized movement disorder centers.
Product overview
Newronika offers a single unified adaptive deep brain stimulation platform called αDBS, which includes multiple integrated components: the adaptive closed-loop stimulation system (core therapy delivery), the patented proportional control algorithm (real-time biomarker tracking), Full-Spectrum Brain Sensing (α/β spectrum capture every 10 minutes), the WebBioBank cloud-based neural data platform (AI-powered data storage and biomarker discovery), and Remote Patient Monitoring (automatic at-home data collection). The system is CE-marked and commercially available in Europe for Parkinson's disease patients, with FDA IDE approval for U.S. clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- αDBS (AlphaDBS): Adaptive deep brain stimulation platform that monitors brain signals in real-time and automatically adjusts stimulation parameters for patients with movement disorders including Parkinson's disease
- WebBioBank™
Products and services
- αDBS (AlphaDBS) Adaptive Deep Brain Stimulation Platform Implantable adaptive deep brain stimulation system for Parkinson's disease that continuously monitors brain signals minute-by-minute and automatically adjusts stimulation in real time, responding to each patient's unique neural biomarkers through a patented proportional control algorithm. CE-marked and sold to hospitals and specialized movement disorder clinics.
- WebBioBank Cloud-Based Neural Data Platform
Quantifiable outcome
- 86% patient preference for αDBS over conventional DBS in double-blind randomized crossover study (N=19)
- +3 more outcomes
Companies that use Newronika
Customer profileSegments3 records
Ideal customer profiles2 records
Newronika technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Newronika partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Fondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicocoreOne of Italy's leading research institutions and founding research partner of Newronika spin-off. Source of two decades of foundational R&D for adaptive DBS technology.
- University of MilancoreLeading Italian university and founding research partner of Newronika spin-off. Co-founders include faculty from University of Milan conducting neuromodulation research.
Scale indicators13 records
Recent moves7 records
Expansion highlights6 records
Newronika competitors and assessment
Company assessmentDirect peers
- Medtronic: The global leader in deep brain stimulation with the Activa and Percept PC (with BrainSense adaptive sensing) platforms. Direct competitor in the DBS market targeting Parkinson's disease and other movement disorders, with substantially greater commercial scale and an early adaptive-sensing feature in Percept PC.
- Saluda Medical: Develops the Evoke closed-loop spinal cord stimulation system using neural-response feedback — the closest direct analog to Newronika's closed-loop adaptive technology in the neuromodulation space. Comparable business model and underlying sensing-and-adapt paradigm, applied to a different target indication.
- Boston Scientific: Markets the Vercise and Vercise Genus DBS systems, with directional leads and Bluetooth-based programming. Direct competitor in the Parkinson's DBS market with established commercial presence and ongoing platform development.
- PINS Medical: Chinese DBS device manufacturer with a portfolio of implantable pulse generators and electrode leads for Parkinson's disease and other movement disorders. Direct DBS competitor, primarily serving China and select Asia-Pacific markets.
- SceneRay: China-based developer of DBS systems for Parkinson's disease, epilepsy, and other neurological indications. Direct competitor in the DBS market, primarily serving the Chinese market with growing international presence.
- Abbott: Markets the Infinity DBS system following its St. Jude Medical acquisition. Direct competitor in the DBS space with established hospital sales channels and a broad neuromodulation portfolio spanning DBS and spinal cord stimulation.
Emerging players
- NeuroPace: Developer of the RNS System, a closed-loop responsive neurostimulation device for epilepsy. Applies the same sensing-and-adapt paradigm as αDBS but targets a different indication (epilepsy vs. Parkinson's). Publicly traded (NPCE), providing a valuation benchmark for closed-loop neurostimulation.
- Functional Neuromodulation: Focused on DBS for cognitive and memory disorders including Alzheimer's disease. Applies DBS technology to neurological indications beyond Parkinson's, partially overlapping with Newronika's potential indication expansion roadmap.
- Aleva Neurotherapeutics: Swiss developer of directional DBS leads and full DBS systems (directSTIM, direcTONIC). Comparable in size and stage to Newronika, with overlap in DBS innovation focus though without the same closed-loop sensing emphasis.
Others
- Blackrock Microsystems: Provider of neural interface technology, electrodes, and research tools used in DBS and brain-computer interface research. Adjacent/enabling player supplying components and technology that underpin DBS and neuromodulation R&D, including work with academic partners that overlap with Newronika's institutional research base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Newronika social profiles
Digital presenceNewronika compliance and trust
Trust signalCompliance2 records
Newronika financial estimates
Financial estimateRevenue estimate
Valuation estimate
Newronika leadership team
Management profileNumber of profiles
Profiles10 records
Newronika subsidiaries and ownership
Company hierarchySubsidiaries1 record
Newronika funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Newronika M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Newronika
What does Newronika do?
Newronika develops and sells the αDBS (AlphaDBS) adaptive deep brain stimulation platform, an implantable neurostimulation system for Parkinson's disease patients. The platform combines closed-loop implantable hardware, a patented proportional control algorithm, full-spectrum brain sensing, and the WebBioBank cloud-based AI data platform, with remote patient monitoring capabilities. The system is CE-marked and commercially available in the European Economic Area, sold to hospitals and specialized movement disorder centers.
Is Newronika a public or private company?
Newronika is a private company. It is classified as venture growth investor backed and is currently operating.
When was Newronika founded?
Newronika was founded in 2011. It employs 11 to 50 people.
Where is Newronika based?
Newronika is headquartered in Milan, Italy, in the Europe region.
How does Newronika make money?
Two revenue lines are on record. Adaptive DBS Hardware and Implant Systems are the primary driver. The others are clinical Support and Professional Services.
Who are Newronika's main competitors?
Direct peers on record are Medtronic, Saluda Medical, Boston Scientific, PINS Medical, SceneRay and Abbott. Emerging players are NeuroPace, Functional Neuromodulation and Aleva Neurotherapeutics. Blackrock Microsystems is listed as an others.
Does Newronika have an API?
No public API is recorded for Newronika.
What industry is Newronika in?
Newronika's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 54151 and its SIC code is 7370.